Alnylam Pharmaceuticals, Inc. (ALNY) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Market Cap | 52.09B |
| Enterprise Value | 51.71B |
| P/E Ratio | 66.7 |
| PEG Ratio | 0.03 |
| Price/Sales Ratio | 9.06 |
| Price/Book Ratio | 35.94 |
| Enterprise/Revenue | 8.95 |
| Enterprise/EBITDA | 41.53 |
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | March 31, 2026 |
| Profit Margin | 0.13 |
| Operating Margin | 0.18 |
| Return On Assets | 0.11 |
| Return On Equity | 0.98 |
| Revenue | 3.71B |
| Revenue/Share | 32.26 |
| Gross Profit | 3.04B |
| EBITDA | 631.44M |
| Net Income | 313.75M |
| Diluted EPS | 2.33 |
| Total Cash | 3.01B |
| Total Cash/Share | 22.64 |
| Total Debt | 1.27B |
| Total Debt/Equity | 1.18 |
| Current Ratio | 3.13 |
| Book Value Per Share | 8.09 |
| 52-Week Change | -7.13 |
| 52-Week High | 495.55 |
| 52-Week Low | 273.11 |
| Moving Average 50 Days | 299.85 |
| Moving Average 200 Days | 373.59 |
| Average Volume | 1.12M |
| Shares Outstanding | 133.51M |
| % Held by Institutions | 97.23 |
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |